Metabolite Reference Standards and Reagents: All Compounds
Please note that this program has ended. The Metabolite Standards Synthesis Cores (MSSCs) are shipping out the remaining inventory, but will not be making more. We are furthermore no longer accepting nominations for new syntheses.
You may request compounds via the links below, but note that some are no longer available.
You may request compounds via the links below, but note that some are no longer available.
Search:
Fields searched: | Browse by Pathway Cassette |
Structure | Compound ID | Common Name | InChiKey | Isotopic Label Type | Isotopic Label Position | Pathway Cassette | MSSC | Status | Request this compound |
---|---|---|---|---|---|---|---|---|---|
40 | 10-Formyl-tetrahydrofolic acid | AUFGTPPARQZWDO-YUZLPWPTSA-N | Folates/1C metabolism | RTI | completed | ||||
178 | 11-keto-1,6,7-trideuterotestosterone | WTPMRQZHJLJSBO-FLDABYKKSA-N | Steroids/bioactive lipids | RTI | completed | ||||
181 | 11β-Hydroxyandrostenedione | WSCUHXPGYUMQEX-KCZNZURUSA-N | unlabelled parent * | Steroids/bioactive lipids | RTI | completed * | |||
180 | 11β-Hydroxyandrostenedione-d3 | 2H | carbons 1,6,7 | Steroids/bioactive lipids | RTI | completed ‡ | |||
44 | 11β-hydroxyandrostenedione (d-4) | WSCUHXPGYUMQEX-KCZNZURUSA-N | 2H | at carbons 1,2,6,7 | Steroids/bioactive lipids | RTI | nominated † | ||
213 | 13CD3-QA Iodide | CSRAQSNOQWXULC-HBKQTYJLSA-M | 13C + 2H | both on one mehyl group | Reagents | SRI | completed | ||
225 | [15N2,13C]-5-Carboxycytosine | BLQMCTXZEMGOJM-QIOHBQFSSA-N | 15N, 13C | SRI | completed | ||||
226 | [15N2,13C]-5-Formylcytosine | FHSISDGOVSHJRW-QIOHBQFSSA-N | 15N, 13C | SRI | completed | ||||
83 | 15N-Cholamine Bromide | VSZWLDAGOXQHNB-NWZHYJCUSA-M | 15N | Please see Anal Chem. 2013 Sep 17;85(18):8715-21. | Reagents | SRI | completed | ||
214 | 15NQDA | CSRAQSNOQWXULC-XOJMRSMASA-M | 15N | 2-15Naminooxyethyl | Reagents | SRI | completed | ||
179 | 18-Hydroxy-1,18,18-trideuterocorticosterone | WTPMRQZHJLJSBO-BYUZBNOLSA-N | Steroids/bioactive lipids | RTI | synthesis in process | ||||
177 | 18-hydroxy-1,18,18-trideuterocortisol | HESFZGWRDUVOMS-YTTWDCMTSA-N | Steroids/bioactive lipids | RTI | synthesis in process ‡ | ||||
176 | 18-hydroxy-1,6,7-trideuterocortisol | HESFZGWRDUVOMS-AZFBHEKGSA-N | 2H | Steroids/bioactive lipids | RTI | synthesis in process ‡ | |||
187 | 18-Hydroxycorticosterone | HFSXHZZDNDGLQN-ZVIOFETBSA-N | unlabelled parent * | Steroids/bioactive lipids | RTI | synthesis in process * | |||
186 | 18-Hydroxycortisol | HESFZGWRDUVOMS-UKSDXMLSSA-N | unlabelled parent * | Steroids/bioactive lipids | RTI | synthesis in process * | |||
45 | 18-oxo-tetrahydrocortisol | ONUUOQCMEFWOSB-ASTGPZOCSA-N | NA | NA | Steroids/bioactive lipids | RTI | synthesis in process | ||
43 | 18β-hydroxycortisol | HESFZGWRDUVOMS-FJNAKSJRSA-N | either -d3 or 13C3 or greater | any non-exhangeable position | Steroids/bioactive lipids | RTI | synthesis in process † | ||
217 | 1-Monoethyl malate | FHHFKGGCXNOIAY-PTQBSOBMSA-N | 13C | 1 position of malate | Krebs cycle | SRI | completed | ||
77 | 2-hydroxyglutaric acid | HWXBTNAVRSUOJR-UHFFFAOYSA-N | 13C | uniform enrichment | Krebs cycle | SRI | completed | ||
7 | 2-keto-3-deoxygluconate | WPAMZTWLKIDIOP-WVZVXSGGSA-N | Miscellaneous/drugs | SRI | completed | ||||
221 | 2-Oxo-20-trihydroxy-leukotriene B4 | QVZXILIWUPKGPA-CYHXRQOESA-N | Steroids/bioactive lipids | nominated | |||||
8 | 3-Deoxyarabino-hexonic acid | YGMNHEPVTNXLLS-VAYJURFESA-N | NA | NA | Miscellaneous/drugs | SRI | completed | ||
222 | 5-carboxy-2’-deoxy-Cytidine | FHPQEVWDHUHVGT-RRKCRQDMSA-N | 13C | all carbons on the cytosine | Epigenetics | synthesis in process | |||
215 | 5-carboxylcytosine | BLQMCTXZEMGOJM-UHFFFAOYSA-N | Epigenetics | SRI | completed | ||||
173 | 5-Formimino-tetrahydrofolic acid | YCWUVLPMLLBDCU-OLZOCXBDSA-N | Folates/1C metabolism | RTI | completed ‡ | ||||
223 | 5-formyl-2’-deoxy-Cytidine | QBADNGFALQJSIH-XLPZGREQSA-N | 13C | All of the cytosine ring | Epigenetics | synthesis in process | |||
216 | 5-formylcytosine | FHSISDGOVSHJRW-UHFFFAOYSA-N | Epigenetics | SRI | completed | ||||
224 | 5-Hydroxymethyl-2''-deoxycytidine-4,5,hydroxymethyl-13C3 | 13C3 | synthesis in process ‡ | ||||||
55 | 6-phosphogluconic acid | BIRSGZKFKXLSJQ-SQOUGZDYSA-N | 13C | uniform enrichment | Pentose phosphate: oxidative branch | SRI | completed | ||
54 | 6-phosphogluconolactone | IJOJIVNDFQSGAB-SQOUGZDYSA-N | 13C | uniform enrichment | Pentose phosphate: oxidative branch | SRI | completed | ||
74 | (6R)-5,10-methylenetetrahydrofolate | QYNUQALWYRSVHF-OLZOCXBDSA-N | 13C | Folates/1C metabolism | RTI | synthesis in process ‡ | |||
175 | (6R,S)-5,10-Methenyl-5,6,7,8-tetrahydrofolic acid, chloride | NDMWNIVQVBEIJX-ZEDZUCNESA-N | Folates/1C metabolism | RTI | completed ‡ | ||||
174 | (6R,S)-5,10-Methylene-5,6,7,8-tetrahydrofolic acid, calcium salt | AKUPTUNGFOADRT-ZEDZUCNESA-L | unlabelled parent * | Folates/1C metabolism | RTI | completed * | |||
218 | Acetaminophen | RZVAJINKPMORJF-UHFFFAOYSA-N | Uniformly 13C labeled acetaminophen | All carbon (eight carbon) | Miscellaneous/drugs | nominated | |||
197 | AICA Ribonucleotide | XOGIBYSEXZJKHY-UIPKGFOGSA-N | unlabelled parent * | Nucleotide pathways: purine biosynthesis | RTI | completed * | |||
234 | alpha-keto-beta-methylvalerate-13C6 | t | t | t | branched-chain amino acid oxidation | completed | |||
233 | alpha-ketoisocaproate-13C6 | t | t | t | branched-chain amino acid oxidation | completed | |||
194 | Carbamoyl phosphate | FFQKYPRQEYGKAF-UHFFFAOYSA-N | unlabelled parent * | Nucleotide pathways: pyrimidine biosynthesis | RTI | synthesis in process * | |||
70 | Carbamoyl phosphate | FFQKYPRQEYGKAF-UHFFFAOYSA-N | 13C, 15N | Nucleotide pathways: pyrimidine biosynthesis | RTI | completed | |||
231 | CDP-choline | RZZPDXZPRHQOCG-OJAKKHQRSA-N | 2H | perdeuteration of choline (D13) | synthesis in process | ||||
239 | ceramide C16:0 | YDNKGFDKKRUKPY-TURZORIXSA-N | 13C | in serine subunit (all 3C) | nominated | ||||
202 | Cholamine Bromide | VSZWLDAGOXQHNB-UHFFFAOYSA-M | unlabelled parent * | Reagents | SRI | completed * | |||
9 | Creatine Riboside | BGJFEKXALPJEGN-XVFCMESISA-N | SRI | dropped | |||||
61 | D-Erythrose 4-phosphate | NGHMDNPXVRFFGS-IUYQGCFVSA-N | 13C | uniform enrichment | Pentose phosphate: non-oxidative branch | SRI | synthesis in process | ||
15 | D-glucose (Uniformly deuterated. 13C labeled at the C3 and C4 positions) | WQZGKKKJIJFFOK-GASJEMHNSA-N | 2H, 13C | [U-D, 3,4-13C]glucose | Glycolysis | NA | declined | ||
196 | Dihydroorotic acid | UFIVEPVSAGBUSI-UHFFFAOYSA-N | unlabelled parent * | Nucleotide pathways: pyrimidine biosynthesis | RTI | synthesis in process * | |||
183 | Dimethyl α-ketoglutarate | TXIXSLPEABAEHP-UHFFFAOYSA-N | unlabelled parent * | Krebs cycle | RTI | completed * | |||
26 | Dimethyl α-ketoglutarate | TXIXSLPEABAEHP-UHFFFAOYSA-N | 13C | 1,2,3,4,5-13C5 | Krebs cycle | RTI | completed | ||
58 | D-Ribose 5-phosphate | KTVPXOYAKDPRHY-SOOFDHNKSA-N | 13C | uniform enrichment | Pentose phosphate: non-oxidative branch | SRI | completed | ||
57 | D-Ribulose 5-phosphate | FNZLKVNUWIIPSJ-UHNVWZDZSA-N | 13C | uniform enrichment | Pentose phosphate: oxidative branch | SRI | completed | ||
60 | D-Sedoheptulose-7-phosphate | CBIDVWSRUUODHL-QTSLKERKSA-N | 13C | either C1+C2 or C3 to C7 | Pentose phosphate: non-oxidative branch | SRI | synthesis in process † | ||
59 | D-Xylulose 5-phosphate | FNZLKVNUWIIPSJ-RFZPGFLSSA-N | 13C | uniform enrichment | Pentose phosphate: non-oxidative branch | SRI | synthesis in process | ||
245 | Epilupeol | MQYXUWHLBZFQQO-ISZJTHHZSA-N | nominated | ||||||
238 | FAICR | ABCOOORLYAOBOZ-KQYNXXCUSA-N | 13C | all 5 of ribose ring | nominated | ||||
237 | FGAM | PMCOGCVKOAOZQM-XVFCMESISA-M | 13C | all 5 of ribose subunit | nominated | ||||
95 | fructose 2,6 bisphosphate | U-13C | U-13C | Glycolysis | SRI | synthesis in process | |||
96 | fructose 2,6 bisphosphate | YXWOAJXNVLXPMU-ZXXMMSQZSA-N | Glycolysis | SRI | synthesis in process * | ||||
53 | Fructose-6-phosphate | BGWGXPAPYGQALX-ARQDHWQXSA-N | 13C | uniform enrichment | Glycolysis | SRI | completed | ||
11 | Fumaric acid (2,3-13C and 2,3-2H labeled) | VZCYOOQTPOCHFL-OWOJBTEDSA-N | 13C, 2H | 2,3 | Krebs cycle | NA | declined | ||
229 | GDP Mannose | MVMSCBBUIHUTGJ-GDJBGNAASA-N | 13C | all 6 position in the mannose subunit | completed | ||||
52 | glucose-6-phosphate | NBSCHQHZLSJFNQ-GASJEMHNSA-N | 13C | uniform enrichment | Glycolysis | SRI | completed | ||
90 | Glucosyl (β) sphingosine (d17:1) | DQIGRQVQNXMBJY-XAYNVVOESA-N | Steroids/bioactive lipids | NA | declined | ||||
232 | iso palmitic acid | ZONJATNKKGGVSU-UHFFFAOYSA-N | 13C | 13,14,15,15'-13C4 | nominated | ||||
76 | Itaconic acid | LVHBHZANLOWSRM-UHFFFAOYSA-N | 13C | uniform enrichment though any 2 positions also would suffice | Krebs cycle | SRI | completed | ||
6 | Malioxamycin | KXQRAPMNPUXYGT-VDTYLAMSSA-N | Miscellaneous/drugs | RTI | completed | ||||
220 | Metabolon Lactone X12063 | IJIWKJRHDDIJKI-HGEVZRBZSA-N | Miscellaneous/drugs | nominated | |||||
219 | mono-ethylfumarate (carbon-13 labeled at the 1 and 4 positions of fumarate) | XLYMOEINVGRTEX-JUAXEOANSA-N | 13C | The 1 and 4 position of fumarate | Krebs cycle | SRI | synthesis in process | ||
198 | NAD+ | BAWFJGJZGIEFAR-NNYOXOHSSA-O | unlabelled parent * | Redox/coenzymes | RTI | synthesis in process * | |||
205 | NAD+ | uniform enrichment | Redox/coenzymes | RTI | synthesis in process ‡ | ||||
81 | NADH | BOPGDPNILDQYTO-NNYOXOHSSA-N | 2H,13C, or 15N or combinations thereof | Any 5-should be more than 4 total | Redox/coenzymes | RTI | synthesis in process † | ||
199 | NADH | BOPGDPNILDQYTO-NNYOXOHSSA-N | unlabelled parent * | Redox/coenzymes | RTI | synthesis in process * | |||
203 | NADH labeled | uniform enrichment | Redox/coenzymes | RTI | synthesis in process ‡ | ||||
82 | NAD+ labeled | BAWFJGJZGIEFAR-NNYOXOHSSA-O | 2H,13C, or 15N or combinations thereof | Any 5-should be more than 4 total | Redox/coenzymes | RTI | completed † | ||
200 | NADP+ | XJLXINKUBYWONI-NNYOXOHSSA-O | unlabelled parent * | Redox/coenzymes | RTI | synthesis in process * | |||
85 | NADPH | ACFIXJIJDZMPPO-NNYOXOHSSA-N | 2H,13C,15N at least 5, in any combination | any 5 atoms or more | Redox/coenzymes | RTI | synthesis in process † | ||
201 | NADPH | uniform enrichment | Redox/coenzymes | RTI | synthesis in process ‡ | ||||
206 | NADPH | ACFIXJIJDZMPPO-NNYOXOHSSA-N | unlabelled parent * | Redox/coenzymes | RTI | synthesis in process * | |||
204 | NADP+ labeled | uniform enrichment | Redox/coenzymes | RTI | synthesis in process ‡ | ||||
84 | NADP-stable isotope label | XJLXINKUBYWONI-NNYOXOHSSA-O | 1H,13C,15N or any combination thereof | and that are stable to back-exchange | Redox/coenzymes | RTI | synthesis in process † | ||
243 | Nicotinamide | DFPAKSUCGFBDDF-UHFFFAOYSA-N | 13C | 4 | nominated | ||||
72 | Orotic-4,5,6-carboxy-13C4 Acid Monohydrate | PXQPEWDEAKTCGB-UHFFFAOYSA-N | 13C | Nucleotide pathways: pyrimidine biosynthesis | RTI | completed | |||
236 | Phosphoribosyl pyrophosphate | : PQGCEDQWHSBAJP-TXICZTDVSA-N | 13C | all 5 C | nominated | ||||
235 | Phthioceranic Acid (C40) | MUYDCSADWYJZFO-FDISYFBBSA-N | nominated | ||||||
212 | QDA Iodide | CSRAQSNOQWXULC-UHFFFAOYSA-M | unlabelled parent * | Reagents | SRI | completed | |||
5 | rel-[13C]Tetrahydroxyphenanthrene | NXXFPJMAQQHDHQ-OANWKOAXSA-N | 13C6 | ring-13C6 | Miscellaneous/drugs | SRI | synthesis in process | ||
182 | rel-Tetrahydroxyphenanthrene | unlabelled parent * | Miscellaneous/drugs | SRI | synthesis in process * | ||||
27 | Resolvin E1 | AOPOCGPBAIARAV-OTBJXLELSA-N | n/a | n/a | Steroids/bioactive lipids | NA | declined | ||
71 | (S)-4,5-Dihydroorotic-4,5,6,carboxy-13C4 acid | UFIVEPVSAGBUSI-UHFFFAOYSA-N | 13C | Nucleotide pathways: pyrimidine biosynthesis | RTI | completed | |||
210 | Symmetric Dimethylarginine | HVPFXCBJHIIJGS-LURJTMIESA-N | Epigenetics | nominated | |||||
211 | Symmetric Dimethylarginine labeled | HVPFXCBJHIIJGS-LURJTMIESA-N | 13C | All carbons | Epigenetics | nominated | |||
73 | U13C-AICA Ribonucleotide | NOTGFIUVDGNKRI-UUOKFMHZSA-N | 13C | Nucleotide pathways: purine biosynthesis | RTI | completed | |||
228 | UDP-galactose | HSCJRCZFDFQWRP-UHFFFAOYSA-N | 13C | all 6 C in hexose | nominated | ||||
227 | UDP-glucose | HSCJRCZFDFQWRP-JZMIEXBBSA-N | 13C | glucose subunit, all 6 positions | nominated | ||||
230 | UDP-NAcglucosamine | LFTYTUAZOPRMMI-CFRASDGPSA-N | 13 | 13C6 hexose | nominated | ||||
240 | α-ketoisocaproate | BKAJNAXTPSGJCU-UHFFFAOYAG | 13C | all 6 C | nominated | ||||
241 | α-keto-β-methylvalerate | JVQYSWDUAOAHFM-UHFFFAOYSA-N | 13C | all 6 C | nominated |
Number of records: 96
* This non-target unlabelled compound was analyzed by chromatographic and spectral methods as appropriate but was not certified by GLP protocols.
† One of more compounds were approved for synthesis based on this nomination. Click the common name for details.
‡ This compound was approved for synthesis based on the nomination of a different compound, or a nomination that was not specific.